Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Prostate Specific Antigen
100%
Bladder Cancer
88%
Charlson Comorbidity Index
88%
Lower Urinary Tract Symptom
88%
Geriatric Assessment
88%
Blood Stasis
88%
Gemcitabine
88%
Salvage Therapy
88%
Recurrence Risk
88%
Bladder Tumor
88%
Prostate Hypertrophy
66%
Patient Characteristics
49%
Fulguration
44%
Odds Ratio
33%
Recurrent Disease
29%
Urinary System
29%
Non Muscle Invasive Bladder Cancer
25%
Surgeon
22%
Radical Nephrectomy
17%
Urogenital Tract Cancer
17%
Nephroureterectomy
17%
Prostatectomy
17%
Chi Square Test
17%
Prostate Cancer
14%
Medical Record
14%
Univariate Analysis
14%
Physical Examination
14%
Progression Free Survival
12%
Spontaneous Remission
12%
Bladder Neck
12%
Logistic Regression Analysis
11%
Oxidoreductase
11%
Adenoma
11%
Transurethral Resection
11%
Surgery
11%
Enuresis
8%
Urine Incontinence
8%
International Prostate Symptom Score
7%
Cancer Diagnosis
7%
Pharmacology, Toxicology and Pharmaceutical Science
Gemcitabine
100%
Transitional Cell Carcinoma
88%
Recurrence Risk
88%
Bladder Cancer
88%
Prostate Specific Antigen
88%
Bladder Tumor
88%
Overall Survival
88%
Urine Incontinence
88%
Stress Incontinence
88%
Lower Urinary Tract Symptom
88%
Clinical Trial
88%
Enuresis
59%
Remission
25%
Non Muscle Invasive Bladder Cancer
25%
Pembrolizumab
22%
Prostate Hypertrophy
22%
Prostate Cancer
14%
Mixed Incontinence
14%
Progression Free Survival
12%
Paclitaxel
11%
Immunomodulating Agent
11%
Randomized Controlled Trial
11%